{"relation": [["", "Number of Participants Analyzed [units: participants]", "Change in Hemoglobin Level From Study Entry [units: g/dL] Median (Inter-Quartile Range)", "Change in HGB at Week 4 (n=65)", "Change in HGB at Week 8 (n=65)", "Change in HGB at Week 12 (n=63)", "Change in HGB at Week 16 (n=60)", "Change in HGB at Week 20 (n=55)", "Change in HGB at Week 24 (n=51)", "Change in HGB at Week 28 (n=45)", "Change in HGB at Week 32 (n=38)", "Change in HGB at Week 36 (n=39)", "Change in HGB at Week 40 (n=34)", "Change in HGB at Week 44 (n=31)", "Change in HGB at Week 48 (n=32)", "Change in HGB at Week 52 (n=31)", "Change in HGB at Week 76 (n=29)"], ["NTZ/PEG/RBV", "67", "", "-0.1 (-0.6 to 0.4)", "-2.1 (-3.0 to -1.1)", "-2.5 (-3.5 to -1.8)", "-2.5 (-3.5 to -1.4)", "-2.5 (-3.8 to -1.3)", "-2.4 (-3.2 to -1.3)", "-2.5 (-3.4 to -1.6)", "-2.7 (-3.4 to -1.7)", "-2.5 (-3.9 to -1.7)", "-2.6 (-3.4 to -2.1)", "-2.6 (-3.9 to -1.6)", "-2.7 (-3.4 to -1.9)", "-2.9 (-3.8 to -1.6)", "-0.9 (-1.3 to -0.5)"]], "pageTitle": "Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00991289?sect=Xc015&view=results", "hasHeader": true, "headerPosition": "FIRST_ROW", "tableType": "RELATION", "tableNum": 19, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989510.73/warc/CC-MAIN-20150728002309-00085-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 859362068, "recordOffset": 859351769, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Participant Flow: \u00a0 Overall Study Participants received nitazoxanide (NTZ) alone for 4 weeks followed by up to 48 weeks of NTZ with pegylated interferon (PEG) and ribavirin (RBV). Participants who did not achieve early virologic response (EVR) at Week 16 or had detectable hepatitis C virus (HCV) viral load at Week 28 discontinued treatment. NTZ/PEG/RBV Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Men and women at least 18 years of age with genotype 1 hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection and naive to previous HCV treatment were recruited for participation in this study. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow", "textAfterTable": "\u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered. Reporting Groups \u00a0 Description NTZ/PEG/RBV Participants received nitazoxanide (NTZ) alone for 4 weeks followed by up to 48 weeks of NTZ with pegylated interferon (PEG) and ribavirin (RBV). Participants who did not achieve early virologic response (EVR) at Week 16 or had detectable hepatitis C virus (HCV) viral load at Week 28 discontinued treatment. Baseline Measures \u00a0 \u00a0 NTZ/PEG/RBV \u00a0 Number of Participants \u00a0 [units:\u00a0participants] \u00a0 67 \u00a0 Age \u00a0 [units:\u00a0years] Mean (Standard Deviation)", "hasKeyColumn": false, "keyColumnIndex": -1, "headerRowIndex": 0}